Miriam T Levy
Overview
Explore the profile of Miriam T Levy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark P, Valery P, Strasser S, Weltman M, Thompson A, Levy M, et al.
Drug Alcohol Rev
. 2024 Aug;
43(6):1559-1572.
PMID: 39091194
Introduction: Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct-acting antiviral (DAA) therapy outcome and the clinical...
2.
Hume S, Wong D, Yuen M, Jackson K, Bonanzinga S, Vogrin S, et al.
Liver Int
. 2024 Jul;
44(10):2605-2614.
PMID: 39007640
Background And Aims: Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core-related antigen (HBcrAg) level as a biomarker for...
3.
Clark P, Valery P, Strasser S, Weltman M, Thompson A, Levy M, et al.
J Gastroenterol Hepatol
. 2023 Dec;
39(3):568-575.
PMID: 38114452
Background: Direct-acting antiviral (DAA) therapies for hepatitis C virus infection (HCV) lead to excellent rates of sustained virological response (SVR). However, loss to follow-up (LTFU) for SVR testing remains a...
4.
McNamara J, Joseph R, Stratton E, Levy M, Prakoso E
J Gastrointest Cancer
. 2023 Dec;
55(1):188-189.
PMID: 38064167
No abstract available.
5.
Yeoh Y, Dore G, Lockart I, Danta M, Flynn C, Blackmore C, et al.
Intern Med J
. 2023 Oct;
54(4):602-612.
PMID: 37819787
Background: Viral hepatitis, alcohol-related liver disease (ARLD) and nonalcoholic fatty liver disease (NAFLD) are the main risk factors for hepatocellular carcinoma (HCC) in many countries. In Australia, given the access...
6.
Thompson A, Jackson K, Bonanzinga S, Hall S, Hume S, Burns G, et al.
Hepatol Commun
. 2023 Jul;
7(8).
PMID: 37459199
Background And Aims: HBV RNA in peripheral blood reflects HBV cccDNA transcriptional activity and may predict clinical outcomes. The prospective Melbourne HBV-STOP trial studied nucleot(s)ide analog discontinuation in HBeAg-negative non-cirrhotic...
7.
Maharaj A, Lubel J, Lam E, Clark P, Duncan O, George J, et al.
Hepatol Commun
. 2022 Sep;
6(11):3260-3271.
PMID: 36153817
Although there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study...
8.
Hall S, Burns G, Mooney B, Millen R, Morris R, Vogrin S, et al.
J Infect Dis
. 2022 Sep;
227(1):123-132.
PMID: 36108079
Background: We evaluated the patterns of peripheral Toll-like receptor (TLR) signaling activity and the expression of TLRs and natural killer (NK) cell activation in a cohort of patients experiencing severe...
9.
Jacob R, Prince D, Pipicella J, Nguyen A, Bagatella M, Alvaro F, et al.
Liver Int
. 2022 Sep;
43(1):60-68.
PMID: 36050826
Background And Aims: Significant barriers exist with hepatitis B (HBV) case detection and effective linkage to care (LTC). The emergency department (ED) is a unique healthcare interaction where hepatitis screening...
10.
Thilakanathan C, Kayes T, Girolamo J, Nguyen V, Glass A, Manandhar S, et al.
Liver Int
. 2022 Jul;
43(1):69-76.
PMID: 35861306
Background And Aims: Achieving Hepatitis B e antigen seroconversion (HBeAg SC) at an earlier age confers a better prognosis. We examined baseline and post-partum factors associated with HBeAg SC after...